DNA production methods
The use of HIC matrix purification and exonuclease treatment effectively addresses the need for high-purity pharmaceutical DNA compositions lacking bacterial origins and markers, ensuring therapeutic efficacy.
Patent Information
- Application Number
- PCT/US2025/054340
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-11-07
- Filing Date
- 2025-11-06
- Publication Date
- 2026-05-15
AI Technical Summary
There is a need for novel therapeutic modalities and methods to address unmet medical needs, particularly in the manufacturing of pharmaceutical DNA compositions that lack bacterial origins of replication and selectable markers, while ensuring high purity and efficiency.
A method involving hydrophobic interaction chromatography (HIC) is used to purify circular, double-stranded DNA (cdsDNA) molecules by contacting a solution containing these molecules with an HIC matrix, followed by collecting purified cdsDNA, which lacks bacterial origins of replication and selectable markers, and optionally subjecting the solution to exonuclease activity to enhance purity.
The method achieves high purity and efficiency in producing pharmaceutical DNA compositions with at least 85% cdsDNA, minimizing linear and concatemeric DNA, and eliminating endotoxins and proteins, suitable for therapeutic applications.